Slides
Page 1
• Apollo Hospitals Enterprise Limited Earnings Update Q2 FY27
Page 2
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 2 The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward- looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them. This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same. Disclaimer
Page 3
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved Digital Health & Pharmacy Distribution (Apollo HealthCo) Content Financial Performance Snapshot & Business Segment wise Update 4-9 Consolidated Financials 11-12 Healthcare Services 14-23 Diagnostics & Retail Health (AHLL) 25-28 Digital Health & Pharmacy Distribution (Apollo HealthCo) 30-35 Annexure 37-38 3
Page 4
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 4 Apollo HealthCo Healthcare Services Offline PD ^ Online PD^ & 24|7 Total HealthCo AHLL Consolidated 11,910 9,365 615 1,930 2,057 (127) 76,149 38,998 28,845 32,857 4,294 4,012 (in ₹ Mio) Revenue Growth YoY(%) 23% 24% 23% 23% 23% EBITDA(Post Ind AS) Growth YoY(%) Margin 24.0% 5.9% 14.3% Growth YoY(%) Financial Performance Snapshot Q2FY27 PAT 20% 20% 13% 29% 79% 7.1% 15.6% 19% 32% ^PD:- Pharmacy Distribution 12.5% 8.3% 3.6% Vs (710) in Q2 FY26 4,860 6,301 259 1,182 1 1Digital Cash profit of ` 13 mio for the Quarter (excluding ESOP charges).| AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. 75% 62% 6.0%
Page 5
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 5 Apollo HealthCo Healthcare Services Offline PD ^ Online PD^ & 24|7 Total HealthCo AHLL Consolidated 22,678 17,978 1,056 3,644 3,967 (323) 145,468 74,668 55,132 62,628 8,172 7,496 (in ₹ Mio) Revenue Growth YoY(%) 22% 23% 18% 22% 22% EBITDA(Post Ind AS) Growth YoY(%) Margin 24.1% 5.8% 12.9% Growth YoY(%) Financial Performance Snapshot H1FY27 PAT 19% 20% 14% 29% 83% 7.2% 15.6% 22% 33% ^PD:- Pharmacy Distribution 12.9% 8.3% 3.5% 9,649 12,106 263 2,195 1 1Digital Cash loss of `83mio for the Quarter (excluding ESOP charges). |AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations. . 79% 69% Vs (1,442) in H1 FY26 3.2%
Page 6
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 6 Hospitals Capacity Census Beds1 Operational Census Beds Overall Total 65 * 10,733 9,605 Owned Hospitals 48 9,650 8,522 Managed Hospitals 6 806 806 Day Surgery (AHLL) 11 277 277 Largest Pan India Hospital Chain Nashik: 1 Overseas (Managed) Bahrain : 1 Ahmedabad: 3 Bangalore: 5 Chennai: 10 Delhi: 4 Hyderabad: 6 Kolkata: 3 Lucknow: 1 Mumbai: 3 Aragonda: 1 Bacheli: 1 Bhubaneshwar: 1 Bilaspur: 1 Indore: 1 Kakinada: 1 Karur: 1 Ranipet: 1Mysore: 1 Nellore: 1 Madurai: 2 Trichy: 1 Vishakhapatnam: 2Karimnagar: 1 Karaikudi: 1 Pune: 2 Jaipur: 1 Kanpur: 1 Noida: 1 Assam: 2Bhopal: 1 Cochin: 1 Healthcare Services Q2 FY27 Snapshot 185,980 In-patients 73% Occupancy | Established Units 76% ₹ 186,880 Avg Revenue per IP Patient Revenue EBITDA ` 38,998 Mio ` 9,365 Mio 24.0%Margin 23% 20% 1Capacity beds include only census capacity beds and doesn’t include emergency, daycare beds, recovery room, dialysis, endoscopy etc. © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 14% 8% Rourkela: 1 Beds include recently commissioned 5 new hospitals – Pune, Defence Colony, Gachibowli, Sonarpur and Belenus. *12 Cradle Hospitals and 422 beds excluded, as the business is classified under discontinued operations. Jabalpur: 1
Page 7
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved Revenue EBITDA ` 4,294 Mio ` 615 Mio 14.3%Margin 20% 79% 2,922 Diagnostics Centers 196 Dialysis Centers 300 Dental Centers 292 Clinics 7© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved • Outpatient Clinics • Diagnostics • Day Surgery centers • Single Specialty Facilities :- Dialysis, Sugar and Dental Out-of-Hospital care • Pathology – Organized chains represent only ~30% Organizing the unorganized Significant opportunity to grow the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer AHLL: Retail Health Apollo Health & Lifestyle Ltd AHLL Q2 FY27 Snapshot 1. AHLL completed the transfer of its stake in ASPL (Cradle) and AFCPL (Fertility) to Kids Clinic India Limited on October 12, 2026. 2. Total Consideration: Rs 1,550 crs Cash – Rs 764 crs (including Debt transfer of Rs 213 crs) 9.90% equity in combined entity- Rs 786 crs 3.In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly.
Page 8
• •• ,1 ~ ~ ~ ~ -0 ~ ~ • ·~ COV 10 •19 Vae dnatl on Citcle- Me1"'1be-' ••vea ~848.,.... IYlO'\th . Vou can too . ln•t~ f\ t d,s~n ton Can sul t.11i~ Cas h b~ -ck.5 on Ph.arm~c ·1 Produ c ts I 99 9 95 A c, . m Vi ew He alth (' : BO<llkla..bTH U, Record s ;'It Book Doct or by Man-.ge Sym pto m.!i Ola b e t e.s .Ji1.... Buy Medici nes & £s5e n1lals '.1> ~ ~ !; Book Apoll o Do ctor Appointment ~-1 Alw~y~ c.a,ml! abo ut your hc;alt h, w a an : har• to holp ),·ou! t, hi Manish - I• • © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved • Provides comprehensive remote healthcare services. • Offers specialized telehealth solutions like 24/7 Tele-Emergency and Tele-Consultancy. • Expands access to healthcare in distant regions, improving quality of life. • Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs 8 AHL| India’s Largest Omni-channel Healthcare Platform Apollo 24|7 Apollo HealthCo Ltd © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved Virtual Doctor Consultation Online Medicine delivery Patient e-health records Condition management Health Insurance Online Booking : Hospitals & Diagnostics Health Co Q2 FY27 Snapshot Revenue EBITDA ` 32,857 Mio ` 2,840 Mio (excl 24|7 operating cost & ESOP) 8.6%Margin 23% 20% 7,662 Outlets ~15.3% Omni Private label / Generic sales Apollo Telehealth* *Division of AHEL Unmatched Size • 51 Mn.+ Registered Users – ~ 8.7 Lacs Daily Active Users Industry-leading Growth at scale • Platform GMV (Core Segments) (27% YoY Growth) : Rs 5,708 Mn in Q2’ FY27, over Rs. 4,504 Mn Q2’ FY26 (excluding GST impact) Full stack digital healthcare platform • First-in-class AI enabled technologies including India’s first Clinical Intelligence Engine Offline Pharmacy Distribution • Serving 7,662 Operating Stores as on 30th Sep 2026.
Page 9
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 9 Clinical Achievements & Updates Hospitals o Robotic Surgery: Apollo Hospitals, Greams Road, Chennai, crossed 2,000 cumulative robotic-assisted orthopaedic surgeries across knee and hip replacements. o Advanced Stroke Care: Apollo Hospitals, Jayanagar, performed mechanical thrombectomy in a 72-year-old man with Gerstmann syndrome and an MRI-negative acute ischaemic stroke after identifying a middle cerebral artery cortical branch occlusion. Successful recanalisation resulted in complete reversal of neurological deficits o Transplant Excellence: Apollo Hospitals, Greams Road, Chennai, successfully performed bilateral lung transplantation in a 41-year-old woman with end-stage lung disease after 119 consecutive days on VV-ECMO, using a single oxygenator without circuit exchange throughout the bridge to transplantation. Clinical Updates and New Initiatives AHLL o Organised Diagnosticon at Coimbatore and participated in INSHLT, Chennai; achieved an Asia Book of Records entry for Fragile X awareness in Chennai; contributed 4 publications and ~30 podium presentations o Test menu expansion to include CMA 750K Accel (chromosomal variation), TPMT (thiopurine drug guidance), NUDT (drug metabolism), Metanephrines (catecholamine metabolite measurement), Meningioma prognostic FISH panel, CYP3A5 genotyping, Allergy comprehensive panel (20 Allergen), Transplant Molecular testing etc. o Dental Clinical Advisory Board constituted (first meeting: 17 Aug 2026) to drive standardization of clinical practices across the network. Apollo HealthCo o Digital Turns Cash Positive: First pre-ESOP EBITDA-positive quarter, supported by higher volumes and optimised digital spend. o Stronger Pharma Economics: Per-order economics nearly tripled, with higher order values and lower delivery costs. o Efficient Acquisition & Omni-Channel Growth: User acquisition improved as marketing spend declined, while omni-channel users grew YoY . o Diagnostics Growth & Profitability: Strong volume growth, improved contribution margins, and lower rescheduling through the Polygon model. o Consultation & Insurance Growth: Better app search and doctor availability improved conversion, with ~28K online and ~90K physical consultations per month. o Tier 3 Expansion: Scaling to ~50 Tier 3 cities via Apollo Pharmacy, supported by new distribution centres for faster delivery.
Page 10
• © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 10 Consolidated Financials Consolidated Financials
Page 11
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved ` Mio Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol Total Revenues 38,998 4,294 32,857 76,149 EBITDA (Pre 24|7 Cost) 9,365 615 2,840 12,820 margin (%) 24.0% 14.3% 8.6% 16.8% 24/7 Operating Cost (770) (770) ESOP(Non Cash expense) (140) (140) EBITDA 9,365 615 1,930 11,910 margin (%) 24.0% 14.3% 5.9% 15.6% EBIT 7,499 380 1,728 9,607 margin (%) 19.2% 8.8% 5.3% 12.6% PBT 7,123 350 1,608 9,082 margin (%) 18.3% 8.2% 4.9% 11.9% PAT (Reported) 4,860 259 1,182 6,301 Total Revenues 31,690 3,592 26,606 61,888 EBITDA (Pre 24|7 Cost) 7,800 342 2,361 10,503 margin (%) 24.6% 9.5% 8.9% 17.0% 24/7 Operating Cost (935) (935) ESOP(Non Cash expense) (324) (324) EBITDA 7,800 342 1,102 9,244 margin (%) 24.6% 9.5% 4.1% 14.9% EBIT 6,224 108 860 7,191 margin (%) 19.6% 3.0% 3.2% 11.6% PBT 6,061 (49) 735 6,747 margin (%) 19.1% - 2.8% 10.9% PAT (Reported) 4,082 (40) 731 4,773 YOY Growth Revenue 23% 20% 23% 23% EBITDA 20% 79% 75% 29% PAT 19% - 62% 32% Q2FY27 Q2FY26 11 Consolidated Financials Q2FY27 Overall Consolidated Revenue grew by 23% to ` 76,149 mio. EBITDA grew by 29% to ` 11,910 mio. Consolidated PAT grew by 32% to ` 6,301 mio. (` mio) AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations.
Page 12
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved ` Mio Healthcare Services Diagnostics & Retail Health Digital Health & Pharmacy Distribution Consol Total Revenues 74,668 8,172 62,628 145,468 EBITDA (Pre 24|7 Cost) 17,978 1,056 5,464 24,499 margin (%) 24.1% 12.9% 8.7% 16.8% 24/7 Operating Cost (1,581) (1,581) ESOP(Non Cash expense) (240) (240) EBITDA 17,978 1,056 3,644 22,678 margin (%) 24.1% 12.9% 5.8% 15.6% EBIT 14,310 591 3,251 18,152 margin (%) 19.2% 7.2% 5.2% 12.5% PBT 13,663 400 3,006 17,069 margin (%) 18.3% 4.9% 4.8% 11.7% PAT (Reported) 9,649 263 2,195 12,106 Total Revenues 61,042 6,870 51,324 119,236 EBITDA (Pre 24|7 Cost) 14,974 576 4,506 20,056 margin (%) 24.5% 8.4% 8.8% 16.8% 24/7 Operating Cost (1,898) (1,898) ESOP(Non Cash expense) (569) (569) EBITDA 14,974 576 2,040 17,590 margin (%) 24.5% 8.4% 4.0% 14.8% EBIT 11,823 143 1,551 13,517 margin (%) 19.4% 2.1% 3.0% 11.3% PBT 11,391 (122) 1,305 12,574 margin (%) 18.7% - 2.5% 10.5% PAT (Reported) 7,905 (104) 1,300 9,100 YOY Growth Revenue 22% 19% 22% 22% EBITDA 20% 83% 79% 29% PAT 22% - 69% 33% H1FY26 H1FY27 12 Consolidated Financials H1FY27 Overall Consolidated Revenue grew by 22% to ` 145,468 mio. EBITDA grew by 29%to ` 22,678 mio. Consolidated PAT grew by 33% to ` 12,106 mio. (` mio) HCS Health Co AHLL Gross Debt 26,360 1,472 3,485 23,426 796 805 2,934 676 2,679 31,317 6,289 Cash & Cash Equivalents* Net Debt Consol Gross Debt Consol Net Debt *Includes investments in Liquid funds and FDs of ` 19,154 mio. AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative- period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations.
Page 13
• © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 13 Healthcare Services Hospitals
Page 14
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved ` Mio Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY No of Hospitals 48 45 48 45 Operating beds 8,522 8,050 6% 8,522 8,050 6% Occupancy 73% 69% 71% 67% IP Discharges 185,980 162,984 14% 357,642 314,501 14% ALOS 3.07 3.14 -2% 3.08 3.14 -2% Avg revenue per In Patient (`) 186,880 173,258 8% 186,760 172,810 8% Revenue 38,998 31,690 23% 74,668 61,042 22% EBITDA (Post Ind AS 116) 9,365 7,800 20% 17,978 14,974 20% margin (%) 24.0% 24.6% -60 bps 24.1% 24.5% -45 bps EBIT 7,499 6,224 20% 14,310 11,823 21% margin (%) 19.2% 19.6% -41 bps 19.2% 19.4% -20 bps PBT 7,123 6,061 18% 13,663 11,391 20% PAT 4,860 4,082 19% 9,649 7,905 22% Margin 12.5% 12.9% -42 bps 12.9% 12.9% -3 bps 14 Capital employed (ROCE – Q2FY27) * capital employed excludes CWIP of ` 15,288 mio toward new projects under development Healthcare Services Revenue grew by 23% in Q2FY27 . Overall Volume grew by 14% (Established Units Volume grew by 10%, price of 4% and Case mix /payor mix of 5%). Healthcare Services Financials ` 96,351 ROCE 29.7% (` mio) Average Revenue per In patient grew by 8%to `186,880 in Q2FY27. Revenue growth driven by Robust volume increase in CONGO Specialties and high Complexity Clinical work aided by key specialties like Oncology (28% growth), Gastro (27%), Cardiac and Ortho (20%) and Urology (26%). New Units pre – operative expenses / losses in Q2FY27 is ` 348 mio. EBITDA margin of established units at 25.8% in Q2FY27.
Page 15
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 15 Inpatients Revenue Mix H1FY27 * Oncology includes Radiotherapy and Chemotherapy Cardio Onco* Neuro Ortho Gastro Internal Med Others Gen Surg Obs&Gynac Nephro Uro Transplts Paed 8% Inpatient Specialty Mix Self Pay Insurance PSU & Govt IPS Inpatient Payor Mix 10% 11% 18% 17% 7% 4% 4% 4% 4% 3%3% 39% 46% 9% 6% 7%
Page 16
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 16 Healthcare Services: Expansion Plan Current Beds (Total Census) – Q2FY27 9,605 ~13,800Post Expansion Includes Owned, Managed and AHLL +4,198* Total Project Cost of ~` 11,150 crs with Balance to be spent of ~`7,100crs. Commissioned 5 new hospitals (~1,000 Census beds) Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros Of the total ~1,000 Census beds, excluding Gurgaon, 520 beds have been operationalized, with the remaining 480 beds planned to be progressively activated over the next 12–18 months, in line with the phased ramp-up plan. Location Nature Total Beds Census Beds Project Cost (in Crs) Beds Commissioned (Census) FY26 - FY27 Pune (Phase 1 & Phase 2) Asset Light,Green Field 384 305 ₹ 665 125 Sonarpur, Kolkata Asset Light,Green Field 270 220 ₹ 310 100 Gachibowli, Hyderabad Asset Light,Green Field 375 300 ₹ 550 155 Defence Colony, Delhi Asset Light,Green Field 42 40 ₹ 65 40 Sarjapur-1 Acquisition 180 150 ₹ 300 100 Gurgaon, NCR Green Field, Acq 469 380 ₹ 1,295 FY26 - FY27 Total 1,720 1,395 ₹ 3,185 520 FY28 - FY29 Jubilee Hills (Expansion) Brownfield 100 80 ₹ 230 Secunderabad (Expansion) Brownfield 100 80 ₹ 70 Malleswaram & Mysore Expansion Brownfield 140 125 ₹ 205 Indore Oncology (Expansion), Madhya Pradesh Brownfield 60 42 ₹ 70 FY28 - FY29 Total 400 327 ₹ 575 FY30-31 Sarjapur-2 Greenfield 455 360 ₹ 944 OMR, Chennai Greenfield 600 500 ₹ 945 Varanasi, U.P Greenfield 400 300 ₹ 640 Lucknow (Expansion), U.P Brownfield 200 160 ₹ 320 Worli, Mumbai Greenfield 575 500 ₹ 1,315 Hyderabad (Comprehensive Cancer Care + Proton) Brownfield 140 110 ₹ 570 Guwahati (Expansion) Brown Field 88 82 ₹ 100 Indore, Madhya Pradesh Green Field 200 164 ₹ 350 Dwarka, Delhi Land lease, Green Field 600 480 ₹ 1,290 Delhi Cancer Centre & Proton GreenField 100 100 ₹ 573 Ranchi, Jharkhand Green Field 320 240 ₹ 345 FY30-31 Total 3,678 2,996 ₹ 7,393 Grand Total 5,798 4,718 ₹ 11,152 Total Operating / census beds under expansion 4,718 beds, operationalized 520 beds – Balance → 4,198*
Page 17
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 17 Healthcare Services : Operational Snapshot Ahmedabad Bangalore Chennai Delhi Hyderabad Kolkata Lucknow Mumbai Bhubaneshwar Bilaspur Indore Kakinada Karur Mysore Nashik Nellore Madurai Trichy VishakhapatnamKarimnagar Karaikudi Metros: Chennai, Hyderabad, Bangalore, Mumbai, Kolkata and NCR Non Metros (includes Tier1 & Tier2 cities) Ahmedabad, Bhubaneshwar, Lucknow, Indore, Guwahati, Madurai, Trichy, Nellore,Vizag, Kakinada, Mysore, Nashik, Pune, Bilaspur, Rourkela, Karimnagar, Karur and Karaikudi. Guwahati ^ is net of fees paid to fee for service doctors which is netted off in the reported revenues ARPP -IP^ Occupancy Operating Beds 4,966 Non Metros6 Metros 3,556 74% 70% ` 222,626 ` 133,654 |1Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control Rourkela Q2FY27 ^Avg revenue per In Patient | Incls New Hospitals Pune Established Units Occupancy 76% 69% Above includes New Hospitals ^ is net of fees paid to fee for service doctors which is netted off in the reported revenues Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 8,522 8,050 5.9% 8,522 8,050 5.9% Bed Occupancy Rate (%) 73% 69% 71% 67% Inpatient volume 185,980 162,984 14.1% 357,642 314,501 13.7% Inpatient ALOS (days) 3.07 3.14 -2.3% 3.08 3.14 -1.7% Total Net Revenue (` mio)(1) 42,324 34,811 21.6% 81,217 67,055 21.1% Avg revenue per In Patient 186,880 173,258 7.9% 186,760 172,810 8.1% Pan India
Page 18
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 18 Tamil Nadu Region Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore Nellore ARPP-IP ^ Occupancy Operating Beds 1,340 Chennai 72% ARPP-IP ^ Occupancy Operating Beds 665 Others 69% 158,337 Expansion Plan H1 FY27 ^Avg revenue per In Patient 1,340 Current Beds Post Expansion 1,840 2,005 2,505 Chennai Total +500 Chennai Madurai Madurai Trichy Karur Nellore Karaikudi 237,740 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 2,005 2,066 -3.0% 2,005 2,066 -3.0% Bed Occupancy Rate (%) 72% 63% 71% 62% Inpatient volume 44,707 39,356 13.6% 86,951 76,878 13.1% Inpatient ALOS (days) 2.96 3.05 -3.2% 3.00 3.06 -1.7% Total Net Revenue (` mio) 12,401 10,411 19.1% 23,796 20,235 17.6% Avg revenue per In Patient 217,162 205,263 5.8% 215,290 203,926 5.6% Tamil Nadu Region Location Nature Total Beds Census Beds OMR, Chennai Greenfield 600 500
Page 19
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 19 AP, Telangana Region Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada ARPP-IP ^ Occupancy* Operating Beds 944 Hyderabad 71% 206,279 ARPP-IP ^ Occupancy Operating Beds 503 Others 63% 170,021 Hyderabad Kakinada Vishakhapatnam Expansion Plan Karimnagar H1FY27 ^Avg revenue per In Patient 944 Current Beds Post Expansion 1,359 1,447 1,862 Hyderabad Total +415 #Beds operationalized as on Sep 26:- Gachibowli – 155 beds Hyderabad includes New Unit *Established units Occupancy at 77% Location Nature Total Beds Census Beds Gachibowli, Hyderabad Asset Light,Green Field 375 300 Jubilee Hills (Expansion) Brownfield 100 80 Secunderabad (Expansion) Brownfield 100 80 Hyderabad (Comprehensive Cancer Care + Proton) Brownfield 140 110 Total 715 570 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoYQ2FY26 Operating Beds 1,447 1,290 12.2% 1,447 1,290 12.2% Bed Occupancy Rate (%) 71% 68% 68% 65% Inpatient volume 31,289 25,592 22.3% 60,327 48,863 23.5% Inpatient ALOS (days) 3.00 3.14 -4.5% 2.99 3.16 -5.5% Total Net Revenue (` mio) 7,249 5,567 30.2% 13,800 10,581 30.4% Avg revenue per In Patient 198,406 185,203 7.1% 196,576 183,924 6.9% AP, Telangana Region
Page 20
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 20 Karnataka Region ^ is net of fees paid to fee for service doctors and is netted off in the reported revenues Bangalore Metro:- Bangalore; Non Metro:- Mysore Mysore ARPP-IP ^ Occupancy Operating Beds 668 Bangalore 65% 215,609 ARPP-IP ^ Occupancy Operating Beds 213 Others 75% 136,804 Expansion Plan H1FY27 ^Avg revenue per In Patient 668 Current Beds Post Expansion 1,203 881 1,416 Bangalore Total +535 #Beds Operationalized as on Sep 26:- Sarjapur-1 – 100 beds Bangalore includes New Unit *Established units Occupancy at 74% Location Nature Total Beds Census Beds Malleswaram & Mysore Expansion Brownfield 140 125 Sarjapur-1 Acquisition 180 150 Sarjapur-2 Greenfield 455 360 Total 775 635 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 881 781 12.8% 881 781 12.8% Bed Occupancy Rate (%) 70% 70% 68% 69% Inpatient volume 20,579 17,765 15.8% 39,216 34,718 13.0% Inpatient ALOS (days) 2.75 2.83 -3.1% 2.78 2.85 -2.5% Total Net Revenue (` mio) 4,692 3,721 26.1% 8,987 7,264 23.7% Avg revenue per In Patient 194,937 175,034 11.4% 195,797 175,709 11.4% Karnataka Region
Page 21
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 21 Eastern Region ^ is net of fees paid to fee for service doctors and is netted off in the reported revenues Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela ARPP-IP ^ Occupancy* Operating Beds 836 Kolkata 77% 240,469 ARPP-IP ^ Occupancy Operating Beds 1,147 Others 74% 107,326 Kolkata Bhubaneshwar Bilaspur Guwahati Expansion Plan Rourkela H1FY27 ^Avg revenue per In Patient ; Kolkata ARPP-IP Grossed up for fee-for-service doctor fees. 836 Current Beds Post Expansion 956 1,983 2,425 Kolkata Total +120 #Beds operationalized as on Sep26:- Sonarpur – 100 beds Kolkata includes New Unit *Established units Occupancy at 86% +442 Location Nature Total Beds Census Beds Sonarpur, Kolkata Asset Light,Green Field 270 220 Guwahati (Expansion) Brown Field 88 82 Ranchi, Jharkhand Green Field 320 240 Total 678 542 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 1,983 1,818 9.1% 1,983 1,818 9.1% Bed Occupancy Rate (%) 77% 79% 75% 75% Inpatient volume 40,742 36,361 12.0% 78,110 69,678 12.1% Inpatient ALOS (days) 3.45 3.62 -4.7% 3.50 3.59 -2.4% Total Net Revenue (` mio) 7,906 6,763 16.9% 15,250 12,872 18.5% Avg revenue per In Patient 156,749 148,337 5.7% 157,798 146,833 7.5% Eastern Region
Page 22
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 22 Western Region Metro:- Mumbai; Non Metro:- Nashik, Ahmedabad and Pune ARPP-IP ^ Occupancy Operating Beds 392 Mumbai 76% 208,414 ARPP-IP ^ Occupancy* Operating Beds 573 Others 52% 138,547 Ahmedabad Mumbai Nashik Expansion Plan H1FY27 ^Avg revenue per In Patient 392 Current Beds Post Expansion 892 965 1,645 Mumbai Total +500 +680 Pune# Others includes New Unit *Established units Occupancy at 60% #Beds operationalized as on Sep 26:- Pune – 125 beds Location Nature Total Beds Census Beds Pune (Phase 1 & Phase 2) Asset Light,Green Field 384 305 Worli, Mumbai Greenfield 575 500 Total 959 805 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 965 888 8.7% 965 888 8.7% Bed Occupancy Rate (%) 67% 60% 62% 56% Inpatient volume 17,819 14,929 19.4% 33,189 28,026 18.4% Inpatient ALOS (days) 3.36 3.29 2.0% 3.29 3.26 0.9% Total Net Revenue (` mio) 3,603 2,759 30.6% 6,765 5,223 29.5% Avg revenue per In Patient 172,284 155,429 10.8% 172,675 156,283 10.5% Western Region
Page 23
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 23 Northern Region Metro:- NCR; Non Metro:- Lucknow and Indore Indore ARPP-IP ^ Occupancy Operating Beds 786 Delhi NCR 76% 216,143 ARPP-IP ^ Occupancy Operating Beds 455 Others 72% 128,923 Expansion Plan Delhi Lucknow Indore H1FY27 ^Avg revenue per In Patient 786 Current Beds Post Expansion 1,746 1,241 2,867 Delhi NCR Total +960 +1,626 Delhi NCR includes New Unit *Established units Occupancy at 78% #Beds operationalized as on Sep 26 :- Defence Colony – 40 beds Location Nature Total Beds Census Beds Gurgaon, NCR Green Field, Acq 469 380 Varanasi, U.P Greenfield 400 300 Lucknow (Expansion), U.P Brownfield 200 160 Indore Oncology (Expansion), Madhya Pradesh Brownfield 60 42 Indore, Madhya Pradesh Green Field 200 164 Defence Colony, Delhi Asset Light,Green Field 42 40 Dwarka, Delhi Land lease, Green Field 600 480 Delhi Cancer Centre & Proton GreenField 100 100 Total 2,071 1,666 Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Operating Beds 1,241 1,207 2.8% 1,241 1,207 2.8% Bed Occupancy Rate (%) 77% 72% 75% 71% Inpatient volume 30,844 28,981 6.4% 59,849 56,338 6.2% Inpatient ALOS (days) 2.83 2.75 3.0% 2.83 2.78 1.6% Total Net Revenue (` mio) 6,473 5,590 15.8% 12,619 10,880 16.0% Avg revenue per In Patient 177,965 162,140 9.8% 178,946 163,023 9.8% Northern Region
Page 24
• © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 24 Diagnostics & Retail Health Apollo Health & Lifestyle Ltd
Page 25
ltollo Fertility ~ Cradt e &Children's Hospital gl)A • Apollo S~~~1~m Specialists in Surgery ~A Apollo ® DIAGNOSTICS J.A II o· I . , '"'po o ta y:s1s Clinics © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 25 Primary Care Core Primary Care revenue grew ~5% YoY in H1 FY27 Net addition of 16 Primary Care partners & 7 Dialysis centres to the network in H1 FY27 Plan to launch a few owned clinics by the end of FY27 Diagnostics Specialty Care Executive Summary Net addition of 5 Labs & 416 Collection Centers to the network in H1 FY27 Wellness segment grew by ~32% YoY in H1 FY27 - ~22% of Diagnostics revenue Specialty segment grew by ~39% YoY in H1 FY27. ~28 new specialty tests added to the portfolio Spectra: Renovations planned for multiple centers in upcoming quarters
Page 26
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 26 AHLL Financials Q2FY 27 (` mio) Includes IVF* 26 292 Primary Clinics Sugar Clinics 300 Dental Clinics 196 Dialysis 2,922 Diagnostics 23 Spectra1 3,809 2,893 2,501 753 3,368 228 8,289 3,036 1,758 28,154 810# 86 116,889 35,150 1,418 Network Footfalls / Day Gross ARPP Total 76 Includes BOMA1 Without CRL, Diagnostics Gross ARPT is 950# AHLL revenue & EBITDA grew by 20% & 79% YoY in Q2 FY27 respectively; primarily driven by 24% YoY growth in Diagnostics Primary care revenue and EBITDA grew by 12% and 48% YoY in Q2 FY27 respectively Primary Care Diagnostics Specialty Care Corporate / Intra Group Discontinuing operations AHLL Q2 FY27 Revenue 1387 2269 841 -202 0 4294 EBITDA 305 360 133 -183 0 615 margin (%) 22% 16% 16% - - 14% EBIT 228 275 58 -182 0 380 PAT 196 260 29 -237 -68 180 Q2 FY26 Revenue 1242 1827 734 -212 0 3592 EBITDA 206 220 119 -202 0 342 margin (%) 17% 12% 16% - - 10% EBIT 135 146 34 -207 0 108 PAT 103 130 -20 -215 -86 -88 Growth Revenue 12% 24% 15% - 20% EBITDA 48% 64% 11% - 79% AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly.
Page 27
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 27 AHLL Financials H1FY 27 (` mio) Includes IVF* 27 292 Primary Clinics Sugar Clinics 300 Dental Clinics 196 Dialysis 2,922 Diagnostics 23 Spectra1 3,809 2,716 2,529 671 3,423 224 7,839 2,965 1,749 26,466 809# 87 115,251 32,859 1,435 Network Footfalls / Day Gross ARPP Total 76 Includes BOMA1 Without CRL, Diagnostics Gross ARPT is 955# AHLL revenue & EBITDA grew by 19% & 83% YoY in H1 FY27 respectively; primarily driven by 27% YoY growth in Diagnostics Primary care revenue and EBITDA grew by 12% and 37% YoY in H1 FY27 respectively Primary Care Diagnostics Specialty Care Corporate / Intra Group Discontinuing operations AHLL H1 FY27 Revenue 2652 4272 1645 -398 0 8172 EBITDA 550 640 257 -392 0 1056 margin (%) 21% 15% 16% - - 13% EBIT 403 477 109 -399 0 591 PAT 339 444 47 -484 -177 169 H1 FY26 Revenue 2377 3352 1541 -400 0 6870 EBITDA 403 339 252 -417 0 576 margin (%) 17% 10% 16% - - 8% EBIT 260 198 108 -424 0 143 PAT 192 174 23 -432 -162 -204 Growth Revenue 12% 27% 7% - 19% EBITDA 37% 89% 2% - 83% AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly.
Page 28
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 28 Diagnostics : Key Parameters 1,827 1,768 1,939 2,003 2,269 1 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Gross Revenue (Rs. Mn) 220 191 273 281 360 12.0% 10.8% 14% 14% 16% Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 EBITDA (Rs. Mn) EBITDA Margin % 24,535 23,840 23,908 24,778 28,154 733 724 787 808 810 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Footfalls / Day** Gross ARPV (Rs.) 2,311 2,347 2,387 2,575 2,802 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 EBITDA (INR Mn)1 ~330+ Cities presence 120 Labs 2,802+ Collection Centres 4,470+ Pick-up Points (PUPs) Avg. Footfalls per day & Avg. gross realization per patient (INR)* Network Growth – Collection Centers 1. EBITDA post IND AS 116; * Footfalls and ARPV for diagnostics represent outpatient / external business ~330+ Cities presence Operational footprint (as of September 30, 2026) ~473+ Cities presence +491 Gross Revenue (INR Mn) +24% YoY +64% YoY +15% YoY +21% YoY
Page 29
• © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 29 Digital Health & Pharmacy Distribution Apollo HealthCo
Page 30
~ ~ [» ~ -e ~ @ • ·~ COVI 0- 1 9 VAC.dnatl o n 1n1t,1111 d'"°""' on Conwilt ~ttOt"O Cu hbK h on Pl\.l,m.;w;y Product s ,-. lo t-1 II I 999 .95 c . !!] V1• w He a1th ~. Book LO TM I• Record a ~ Book Doctor by Man-«• Sym pto m~ • Of.a.bet es «f!I Buy Mod lc inos & E»enllal• >11 ,r; Book Apollo Doctor Appoinlmc,nl ,>JI n hi Manish • © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 30 India’s Largest Omni-Channel Healthcare Platform ~51 Mn+ Registrations ~8.7 LakhDaily Active Users ~17,000+ Doctors Apollo 247 Digital Platform Apollo Pharmacy Platform ~15.3% Omni Private label / generics mix - Q2’FY27 7,662 Stores Daily Consultations ~16,400 Daily Medicine Orders ~57,400+ Daily Sample Collections ~3,000+ Virtual Doctor Consultation Online Medicine delivery Patient e-health records Condition management Insurance Online Booking : Hospitals & Diagnostics Added (Q2) 223 Closed (Q2) 1 Telangana: 819 Karnataka: 884 Goa: 47 Kerala: 104 Andaman: 7Kerala: 150 Karnataka: 1,113 Goa: 64 Maharashtra: 277 Gujarat: 243 Rajasthan: 138 Haryana: 118 Punjab: 87 Himachal Pradesh: 11 Chandigarh: 4 New Delhi: 141 Tamil Nadu: 1,371 Puducherry: 25 Andhra Pradesh: 1,078 Telangana: 1,030 Chhattisgarh: 102 Orissa: 213 Madhya Pradesh: 73 Bihar: 33 Tripura: 7 Jharkhand : 46 Assam: 59 Uttarakhand: 49 West Bengal: 954 UP: 269
Page 31
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved ` Mio Offline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247 Total HealthCo Total Revenues 28,845 4,012 32,857 EBITDA (Pre 24|7 Cost) 2,057 783 2,840 margin (%) 7.1% 19.5% 8.6% 24/7 Operating Cost (770) (770) ESOP(Non Cash expense) (140) (140) EBITDA 2,057 (127) 1,930 margin (%) 7.1% - 5.9% EBIT 1,728 PBT 1,608 PAT (Reported) 1,205 Total Revenues 23,347 3,259 26,606 EBITDA (Pre 24|7 Cost) 1,812 548 2,361 margin (%) 7.8% 16.8% 8.9% 24/7 Operating Cost (935) (935) ESOP(Non Cash expense) (324) (324) EBITDA 1,812 (710) 1,102 margin (%) 7.8% - 4.1% EBIT 860 PBT 735 PAT (Reported) 734 Revenue 24% 23% 23% EBITDA (Pre 24|7 Cost) 13% 43% 20% Q2FY27 Q2FY26 31 Apollo HealthCo Financials Q2 FY27 (` mio) HealthCo (Q2’ FY27 vs Q2’ FY26) o Digital became cash positive to Rs 13 Mn in Q2’FY27, reduction in losses by Rs 400 Mn YoY o Health Co Revenue growth @25% growth in Q2’ FY27 vs Q2’ FY26 excluding closure of non profitable corporate partner (Offline PD @ 24%, and Online PD + Apollo 247 @32%) o PAT increased 64% to Rs. 1,205 Mn in Q2’FY 27, compared to Rs. 734 Mn in Q2’FY26. o Additional planned manpower cost and one time LTIP to support future growth in Pharmacy, PL and Generics business segment, resulting in lower EBITDA% in offline during the quarter. Digital Operational Metrics : o Platform GMV grew 20%, while Core Segment GMV grew (27% YoY Growth) : Rs 5,708 Mn in Q2’ FY27, over Rs. 4,504 Mn Q2’ FY26 (excluding GST impact) o Consistent source for new customer acquisition (Polygon & Omni Acquisition strategy) *Core Segment – Pharma & Diagnostics -386 -292 -164 -97 13 Q2'FY26 Q3'FY26 Q4'FY26 Q1'FY27 Q2'FY27 Digital - turning into Break -even 103% *Cash loss/profit is EBITDA post Ind As excluding ESOP expense 1,426 1,662 1,783 1,813 2,070 Q2'FY26 Q3'FY26 Q4'FY26 Q1'FY27 Q2'FY27 HealthCo Cash profit* (in Mn) 1.5X Apollo Telehealth (under AHEL) o Generated Revenue of Rs 134 Mn Q2’FY27
Page 32
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved ` Mio Offline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247 Total HealthCo Total Revenues 55,132 7,496 62,628 EBITDA (Pre 24|7 Cost) 3,967 1,498 5,464 margin (%) 7.2% 20.0% 8.7% 24/7 Operating Cost (1,581) (1,581) ESOP(Non Cash expense) (240) (240) EBITDA 3,967 (323) 3,644 margin (%) 7.2% - 5.8% EBIT 3,251 PBT 3,006 PAT (Reported) 2,222 Total Revenues 44,981 6,343 51,324 EBITDA (Pre 24|7 Cost) 3,481 1,024 4,506 margin (%) 7.7% 16.1% 8.8% 24/7 Operating Cost (1,898) (1,898) ESOP(Non Cash expense) (569) (569) EBITDA 3,481 (1,442) 2,040 margin (%) 7.7% - 4.0% EBIT 1,551 PBT 1,306 PAT (Reported) 1,304 Revenue 23% 18% 22% EBITDA (Pre 24|7 Cost) 14% 46% 21% H1FY27 H1FY26 32 Apollo HealthCo Financials H1 FY27 (` mio) Health Co (H1’ FY27 vs H1’ FY26) o Health Co Revenue growth @23% growth in H1’ FY27 vs H1’ FY26 excluding closure of non profitable corporate partner (Offline PD @ 23%, and Online PD + Apollo 247 @28%) o PAT increased 70% to Rs. 2,222 Mn in H1’FY 27 compared to Rs. 1,304 Mn in H1’FY26. o Reduction in Digital cash loss to Rs 83 Mn in H1’FY27, reduction by Rs 790 Mn Year over Year o Additional planned manpower cost and one time LTIP to support future growth in Pharmacy, PL and Generics business segment, resulting in lower EBITDA% in offline during the quarter. Digital Operational Metrics : o Platform GMV grew 18%, while Core segment GMV* grew (24% YoY Growth) : Rs 10,716 Mn in H1’ FY27, over Rs. 8,670 Mn H1’ FY26 (excluding GST impact) o Consistent source for new customer acquisition (Polygon & Omni Acquisition strategy) *Core Segments – Pharma & Diagnostics -874 -83 H1 FY26 H1 FY27 Digital Cash loss* (in Mn) 90% *Cash loss/profit is EBITDA post Ind As excluding ESOP expense 2,608 3,884 H1 FY26 H1 FY27 HealthCo Cash profit* (in Mn) 49% Apollo Telehealth (under AHEL) o Generated Revenue of Rs 225 Mn for H1’FY27
Page 33
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 33 Apollo HealthCo: Composite Scheme as approved by the Shareholders : 24th June 2026 Undertaking below transactions sequentially, via a scheme of arrangement • Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform (shares of AHEL in Apollo Healthco Ltd) & remote telehealth division of AHEL into New CoStep 1 • Amalgamation of Apollo Healthco Ltd with and into New CoStep 2 • Amalgamation of Keimed Private Limited with and into New Co Step 2 Upon effectiveness of the Scheme (Post Shareholder and NCLT approval), New Co to become an ‘Indian Owned and Controlled Company’ (IOCC), and apply for listing on stock exchanges
Page 34
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 34 • Automatic listing of New Co • Direct participation of AHEL shareholders in New Co ** ** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger/ demerger process is ~ 2.5%. 15% + 2.5%** Effective AHEL plus AHEL shareholders combined holding in resultant New Co at 59.6% AHEL NewCo (AHL + Telehealth + Keimed) Advent 12.1% ESOP 3.0% Keimed promoters and Other SH 25.3% AMPL (100% Holdco of Apollo Pharmacies Ltd (APL) 25.5% AHEL Shareholders 42.1% Composite scheme: Resultant Shareholding Structure as approved by Shareholders Estimated Listing by Q4FY27 post all approvals.
Page 35
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved Offline Pharma Distribution 35 Online Pharma Distribution+247 Total Healthco Keimed Revenue EBITDA,Pre INDAS EBITDA % 24/7 Operating cost ESOP Non Cash charge EBITDA, Pre IndAS EBITDA % 1,90,366 13,749 7.2% 9,083 4.8% -3,488 -1,178 55,132 3,856 7.0% 3,856 7.0% 7,496 1,473 19.6% -1,581 -240 -348 N.M 62,628 5,328 8.5% 3,508 5.6% 86,567 2,739 3.2% -1,581 2,739 3.2% Excluding Digital Combined FY25 1,63,772 11,180 6.8% -4,781 5,322 -1,076 3.2% 6.4% Combined Proforma Financial Metrics (Proposed New Co) H1FY27 (` mio) Combined H1’FY27 1,12,015 8,067 7.2% -1581 -240 6,247 5.6% 6.3% Combined FY26 -240 6.5% - - - - H1’FY27 Company expects to achieve INR 250 bn of revenue and INR 15 bn of EBITDA annualized for Q4 FY27
Page 36
• © 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 36 Annexure
Page 37
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 37 Basis of Consolidation AHEL Standalone Hospitals (100% Ownership) Location Chennai Main Chennai ACI - Chennai Chennai Tondiarpet - Chennai Chennai FirstMed - Chennai Chennai Apollo Children's Hospital Chennai Apollo Specialty, Vanagaram Chennai ASH Perungudi Chennai Women & Child, Shafee Mohammed Road Chennai Apollo Proton & Cancer care Chennai Madurai Madurai Karur Karur Karaikudi Karaikudi Trichy Trichy Nellore Nellore Hyderabad Hyderabad Bilaspur Bilaspur Rourkela Odisha Mysore Mysore Vizag (old & new) Vizag Karim Nagar Karim Nagar Bhubaneswar Bhubaneswar Jayanagar Bangalore Nashik Nashik Malleswaram Bangalore Navi Mumbai Mumbai Pune Pune Defence Colony, Delhi Delhi Financial District Hyderabad Subsidiaries Location Description AHEL Ownership Material Subs Apollo HealthCo Limited India Digital Omni-Channel Healthcare services Platform 98.07% Apollo Health and Lifestyle Ltd India Clinics, Diagnostics and Daycare 100.00% Apollo Multispeciality Hospitals Ltd. Kolkata Hospital 100.00% Apollo Medics Lucknow Hospital 51.00% Imperial Hospital and Research Centre Ltd. Bangalore Hospital 90.00% Apollo Hospitals International Ltd. Ahmedabad Hospital 50.00% Assam Hospitals Ltd Assam Hospital 76.29% Apollo Rajshree Hospital Indore Hospital 54.63% Samudra Healthcare Enterprises Ltd. Kakinada Hospital 100.00% Other Subs Apollo Hospitals (UK) Ltd UK UK Hold Co 100.00% AB Medical Centres Limited Chennai Infrastructure 100.00% Total Health India CSR 100.00% Apollo Hospitals Singapore.PTE Limited Singapore Singapore Hold Co 100.00% Future Parking Pvt Ltd Chennai Infrastructure 100.00% Apollo Home Health care Ltd India Paramedical Services 74.00% Pinakini Hospitals Ltd. Nellore Hospital 80.87% Sapien Bioscienses Pvt Ltd Hyderabad Biobanking tissues 70.00% Apollo Lavasa Health Corporation Ltd Maharashtra Hospital 51.00% Apollo Hospitals North Limited Gurgaon Hospital 100.00% Apollo Hospitals Worli LLP Mumbai Hospital 90.10% Health Axis Hyderabad Healthcare Technologies and Remote healthcare 69.99% Kerala First Health Services Private Limited Kerala Hospital 60.00% Apollo PET-CT Pvt Ltd Hyderabad Diagnostics 100.00% Apollo HealthTech India Digital Omni-Channel Healthcare services Platform 100.00% Associates Location Description Indraprastha Medical Corporation Ltd. Delhi, Noida Hospital 22.03% Family Health Plan Ltd. India TPA, Health Insurance 49.00% ApoKos Rehab Pvt Ltd Hyderabad Rehab Centre 50.00% Stemcyte India Therapautics Pvt Ltd India Stemcell Banking 37.75%
Page 38
© 2026 Apollo Hospitals Enterprise Ltd, All Rights Reserved 38 IND AS - 116 : Impact on P&L and Balance Sheet –H1FY27 Balance sheet Profit & Loss Balance sheet Profit & Loss AHEL Standalone (post IND AS 116) AHEL Consolidated (post IND AS 116) Right of use Asset as of 30 September, 2026 13,693 Lease liabilities as of 30 September, 2026 13,534 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 2,109 Revenue Other expenses (Lease rent) 819 EBITDA 819 Amortisation 493 EBIT 326 Finance charge 580 PBT 255 Right of use Asset as of 30 September, 2026 25,964 Lease liabilities as of 30 September, 2026 25,545 Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) 3,052 Revenue Other expenses (Lease rent) 1,530 EBITDA 1,530 Amortisation 996 EBIT 534 Finance charge 988 PBT 454 (` mio)
Page 39
39 Thank you